



FILE REGISTRY ENTERED T:15:53:59 ON 02 JUL 93
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 1993 American Chemical Society (ACS)

Fan
998114

$\Rightarrow d$ que 124

L22 **STR**




CONNECT IS E1 RC AT 25


NUMBER OF NODES IS 25

L24 1 SEA FILE REGISTRY SSS FUL L22

⇒ d. 124 ide can

! structure from the structure query





1 REFERENCES IN FILE CA (1967 TO DATE)

REFERENCE 1: P CA118(19):192283u

=> file ca

~~FILE 'CA' ENTERED AT 15:54:32 ON 02 JUL 93~~

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 1993 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1967 - 26 Jun 93 (930626/ED) VOL 118 ISS 26.

For OFFLINE Prints or Displays, use the ABS or ALL formats to obtain abstract graphic structures. The AB format DOES NOT display structure diagrams.

=> s l24 or l24/d

1 L24

0 L24/D

~~L25~~ 1 L24 OR L24/D*1 reference from the structure*


=> d l25 cbib abs hitrn

L25 ANSWER 1 OF 1 COPYRIGHT 1993 ACS

CA118(19):192283u amino acid derivatives as HIV-1 protease inhibitors and methods for their synthesis. Kempf, Dale J.; Codacovi, Lynn M.; Norbeck, Daniel W.; Plattner, Jacob J.; Sham, Hing L.; Wittenberger, Steven J.; Zhao, Chen (Abbott Laboratories, USA). Eur. Pat. Appl. EP 486948 A2 27 May 1992, 154 pp. DESIGNATED STATES: R: AT, BE, DE, DK, FR, GB, GR, LU, NL, SE. (Eng). CODEN: EPXXDW. CLASS: ICM: C07D213-26. ICS: C07D213-30; C07D213-40; C07K005-06; A61K037-64; C07D213-56; C07D211-16; C07D277-28; C07D277-30; C07D277-42; C07D417-12. ICI: C07D417-12, C07D277-00, C07D213-00. APPLICATION: EP 91-119464 4 Nov 1991. PRIORITY: US 90-616170 20 Nov 1990; US 91-746020 15 Aug 1991; US 91-777626 23 Oct 1991.

AN CA118(19):192283u

GI

*applicant's
own*

I

AB Certain 2-alkoxy-1,4-butanediamine derivs. are claimed. Specific compds. such as (2S,3S,5S)-2-[N-[N-[N-methyl-N-[(2-pyridyl)methyl]amino]carbonyl]valinyl]amino]-5-[N-[(3-pyridinyl)methoxycarbonyl]amino]-1,6-diphenyl-3-hydroxyhexane I, their salts, and prodrug forms thereof are claimed. The use of such compds. for the manuf. of pharmaceuticals for the treatment of HIV infections and their use for the inhibition of HIV protease are claimed. I in vivo was an HIV-1 protease inhibitor and it was active against HIV-13b.

IT 63941-88-8P 89539-28-6P 144141-82-2P 144142-70-1P
144142-71-2P 144142-72-3P 144162-24-3P 144162-25-4P
144162-32-3P 144162-33-4P 144162-80-1P 144162-81-2P
144162-82-3P 144162-83-4P 144162-84-5P 144162-85-6P
144162-86-7P 144162-87-8P 144162-88-9P 144162-89-0P
144162-90-3P 144162-91-4P 144162-92-5P 144162-93-6P
144162-94-7P 144162-95-8P 144162-96-9P 144162-97-0P
144162-98-1P 144162-99-2P 144163-00-8P 144163-02-0P
144163-03-1P 144185-88-6P 144202-10-8P 144202-11-9P
144239-47-4P

(prepn. of, as intermediate for HIV protease inhibitor)